Solving the 50-year-old puzzle of thalidomide

Nov 17, 2009

Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' could lead to new treatments for Leprosy, Crohn's Disease, AIDS and some forms of cancer.

Thalidomide was used in over 46 countries following its launch in 1957, but its side effects led to over 10000 children being born with and the drug was subsequently banned in 1962. However, the drug is now experiencing a renaissance worldwide, particularly across Africa and South America where new cases of thalidomide-induced limb defects are now occurring. This, argues Dr Neil Vargesson of the University of Aberdeen, raises the urgency for research which can target and isolate the drug's negative side effects.

"The mere mention of thalidomide instils fear in some people to this day as it caused the biggest medical disaster in history," said Vargesson. "However it still raises hopes for the treatments of diseases such as and multiple myeloma."

Dr Vargesson and his team were the first to demonstrate how the drug causes limb defects by targeting immature and now this latest article attempts to link all previous models of thalidomide action together to create one central model. This model proposes that all associated defects could be caused by the same 'common mechanism', primarily an effect on angiogenesis, the growth of new blood vessels.

The understanding that the drug's targeting of blood vessels is a 'common mechanism' and the root cause of thalidomide's other side effects raises the possibility of producing a safer form of the drug which can isolate this mechanism and retain clinical benefits.

"Understanding this mechanism resolves a 50-year-old puzzle," concluded Vargesson, "it answers the questions asked by scientists since the first cases were identified in 1958. The possibility of producing analogues of the drug for targeting specific conditions without the devastating side effects is now a very real possibility."

Source: Wiley (news : web)

Explore further: Prognostic factors identified for peripheral squamous cell carcinomas of the lung

add to favorites email to friend print save as pdf

Related Stories

New insights into thalidomide-birth defect episode

Nov 10, 2008

Scientists in Germany have discovered why the medication thalidomide appeared safe in animal tests before going on the market 50 years ago, only to cause perhaps the most extensive outbreak of drug-induced birth defects in ...

Japan may regulate thalidomide

Jun 13, 2006

Doctors in Japan will be required to register patients who are using the drug thalidomide under proposed regulations, the Japan Times reported.

Thalidomide film to air in Germany

May 19, 2007

A film about the drug thalidomide, which caused thousands of children to be born disabled, will air on German television.

Recommended for you

Video: Is that double mastectomy really necessary?

Oct 24, 2014

When Angeline Vuong, 27,was diagnosed with cancer in one breast earlier this year, her first reaction was "A DOUBLE MASTECTOMY. NOW. " Turns out, she's far from alone: a recent JAMA study of 190,000 breast cancer cases in ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

TheMuskyBuck
not rated yet Nov 17, 2009
How can any product that causes this manner of severe disability still be on the market?

Answer, because it is a drug.

There are many products that exist that are not drugs that are pulled from market by FDA or Health Canada assertions, that in fact turn out to be baseless allegations and there is no recourse for the manufacturers.

However, on the other side you have drugs which maim, kill, injure and disable, yet are left on market knowing full well they will continue to do so.